Introduction
APL, malignancy, HCC, deaths, tumors, hematological tumors
HEPATOCELLULAR CARCINOMA, TUMORS, ACUTE GRANULOCYTIC LEUKEMIA
Hepatocellular carcinoma (HCC) is the sixth most common malignancy, with more than 626,000 new cases per year, and the third leading cause of cancer-related deaths worldwide.In recent years, systematic treatment of advanced HCC has made great progress and includes targeted therapy, immune checkpoint inhibitor (ICI) therapy, and intravenous chemotherapy. The updated results of the IMbrave150 trialChemotherapy for HCC, especially in Asia, is still being studied, although HCC is recognized as one of the most drug-resistant tumors, and many chemotherapy drugs or regimensAll-trans retinoic acid (ATRA), a naturally occurring derivative of vitamin A, is a known strong differentiation inducer. ATRA can activate the heterodimer retinoic acid receptor (RAR)/retinoic X receptor (RXR) by binding to RARs and then binds to the retinoic acid response element (RARE) of the upstream enhancer or promoter of the target gene to activate the target gene. ATRA was first used in the treatment of hematological tumors and has become the standard frontline treatment for acute granulocytic leukemia (APL).